Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01689584
Other study ID # IC 2011-11
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 2, 2012
Est. completion date January 2, 2034

Study information

Verified date January 2024
Source Institut Curie
Contact Sandrine CAPUTO, PhD
Phone 33172389367
Email sandrine.caputo@curie.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some cases to propose a prophylactic surgery.


Description:

Originally, the COVAR study was designed to explore Variants of unknown biological significance (VUS) in BRCA1 (BReast Cancer 1) and BRCA2 (BReast Cancer 2) genes, which are the two major genes identified in hereditary breast and/or ovarian cancers. Since then the study has evolved, in parallel with the evolution of diagnosis, first introducing the PALB2 (Partner and localizer of BRCA2) gene explored in diagnosis since 2015 and now opening the study to all the genes of the panels performed in diagnosis in families with a genetic predisposition syndrome to cancers. The French UMD (Universal Mutation Database)-BRCA1/2, accredited by the French National Cancer Institute, collects anonymous results of genetic tests performed by authorized French laboratories since 1995, giving a real-time vision of families carrying the same VUS. In september 2011, the French UMD-BRCA1/2 database comprised 706 different variants in 1,300 BRCA1 families and 1,089 different variants in 2,101 BRCA2 families. In April 2021, this database contained 1,651 different VSU for BRCA1, 3,015 different VUS for BRCA2, 471 different VUS for PALB2, 68 for RAD51C and 66 for RAD51D. Since 2017, new genes have been explored in the diagnostic setting as they have been reported as predisposing factors for cancers. This list is constantly evolving (Moretta et al., 2018; Dhooge et al., 2020). Data collection for these genes is ongoing and a new database (FrOG) gathering all VUS and mutations identified in the French oncogenetic network has been set up. We have set up a consortium agreement at the end of 2020. This database gathers to date 12 genes and 11,912 different variants in more than 40,000 French families. One of the key measurable parameters for classification of VUS as causal mutations is their co-segregation with the disease. The average size of French families is relatively small, the information of variant co-segregation limited to one family would not be significant. However, the compilation of co-segregation results obtained from several families will allow to obtain more precise and complete estimations of the probability of causality of a given variant. The objective of the COVAR study (COsegregation VARiants) is to organize co-segregation studies of the VUS of the database UMD-BRCA1/2, in order to determine the causal or non-causal nature of these variants. To organize the variants by their clinical relevance, a grid with 5 classes has been used: 1=neutral, 2=likely neutral, 3=VUS, 4=likely causal, 5=causal. The VUS of classes 3 and 4 will be candidates to co-segregation studies because they cannot be used for the genetic counseling. In the selected families the index case will invite the family members (affected and unaffected) to provide a sample of salivary fluid to test the presence of the VUS. The probability that a VUS is causal will be calculated from the cosegregation data using a Bayesian model. The results will be integrated in the multifactorial model described by D. Goldgar, model integrating different parameters as amino acid conservation, structural impact of the variant, co-occurrence with a pathogenic mutation, family history and tumor characteristics.


Recruitment information / eligibility

Status Recruiting
Enrollment 3500
Est. completion date January 2, 2034
Est. primary completion date January 2, 2033
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Index cases: - A person carrying a gene variant class 3 or 4, present and selected in the families of national database of genetic group and cancer (GGC Unicancer) which identifies the variations of all genes from the panel of genes of all French laboratories. - Age = 18 years. - Signed written inform consent "index case" Related parties: - Any relative of an index case with cancer - Any relative without cancer related to an index case, retained by investigators, based on family structure and degree of related compared to the index case - Age = 18 years - Information and signature of the informed consent "selected relatives" Exclusion Criteria: - Minors - Persons deprived of liberty or under guardianship (including curators). - Absence of signed written inform consent

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
salivary kit
The saliva samples will be made of selected related (DNA).

Locations

Country Name City State
France CHU Amiens - Hôpital Nord Amiens
France ICO - Centre Paul Papin Angers
France Centre Hospitalier d'Angoulème Angoulême
France Institut Sainte-Catherine Avignon
France CHU Besançon Besancon
France Groupe Hospitalier Pellegrin Bordeaux
France Institut Bergonié Bordeaux
France Centre Hospitalier Jacques Coeur Bourges
France CHU Morvan de Brest Brest
France Centre François Baclesse Caen
France Centre Hospitalier Hôtel Dieu Chambery
France Centre Jean Perrin Clermont-Ferrand
France Hôpital Civil de Colmar Colmar
France CHU de Dijon Dijon
France CHU de Grenoble Grenoble
France Groupe Hospitalier La Rochelle-Ré-Aunis La Rochelle
France Hôpital Flaubert Le Havre
France Centre Oscar Lambret Lille
France Chru Lille Lille
France CHU Dupuytren Limoges
France Centre Léon Bérard Lyon
France Hospices Civils de Lyon Lyon
France CHU La Timone Marseille
France Institut Paoli Calmettes Marseille
France CHU Arnaud de Villeneuve Montpellier
France Centre Catherine de Sienne Nantes
France Centre Antoine Lacassagne Nice
France CHRU Caremeau Nîmes
France Centre Hospitalier Georges Renon Niort
France Hôpital de la Source Orléans
France Groupe Hospitalier Pitié-Salpêtrière Paris
France HEGP Paris
France Hôpital Saint-Antoine Paris
France Hôpital Saint-Louis Paris
France Hôpital Tenon Paris
France Institut Curie Paris Ile De France
France CHU La Milétrie Poitiers
France CHU de Reims Reims
France ICC Courlancy Reims
France Institut Jean Godinot Reims
France Centre Eugène Marquis Rennes
France CHU de Rouen Rouen
France Institut Curie - Hopital Rene Huguenin Saint-Cloud Haut De Seine
France CHU Saint Etienne Saint-Étienne
France ICO - Centre René Gauducheau Saint-Herblain
France Hopital de Hautepierre - Hôpital Universitaire Strasbourg
France Institut de Cancérologie Strasbourg Europe ICANS Strasbourg
France Institut Claudius Regaud - IUCT - Oncopole Toulouse
France CHU Bretonneau Tours
France CH Simone VEIL Troyes
France Centre Hospitalier de Valence Valence
France Centre Alexis Vautrin Vandoeuvre les Nancy
France CHU Nancy - Hôpital Brabois Vandoeuvre les Nancy
France Gustave Roussy Villejuif
Guadeloupe CHU de Pointe à Pitre Pointe à Pitre
Martinique CHU de Fort de France Fort de France
Réunion CHU Sud Réunion Saint-Pierre Saint-Pierre

Sponsors (1)

Lead Sponsor Collaborator
Institut Curie

Countries where clinical trial is conducted

France,  Guadeloupe,  Martinique,  Réunion, 

Outcome

Type Measure Description Time frame Safety issue
Primary Perform the co-segregation analysis of the selected VUS in the families in order to classify the maximum of variants in terms of their probability to be pathogenic up to 15 years
Secondary • Propose a standardized method to classify VUS that can be integrated into the already existing classification established in the UMD-BRCA1/2 database, with the main focus on variants of class 4 (probably causal) and class 3 (unknown significance). up to 15 years
Secondary • Maximize the number of VUS (both pathogenic and neutral) having associated recommendations for clinical management of at-risk relatives that can be used to guide genetic counselling. up to 15 years
Secondary Assess the penetrance of several class 3 and 4 VUS probably associated with moderate cancer risk, using collected phenotype/genotype data on extended pedigrees. up to 15 years
See also
  Status Clinical Trial Phase
Completed NCT04746794 - Early Detection of GEnetic Risk (EDGE) N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Not yet recruiting NCT06441942 - Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
Terminated NCT04119596 - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting NCT04141462 - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer N/A
Completed NCT02826330 - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting NCT04620278 - Genetic Investigation of Cancer Predisposition
Active, not recruiting NCT02373709 - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Not yet recruiting NCT06089421 - Genetic Information Assistant in Telegenetics N/A
Completed NCT05975489 - Genetics in the Effect of Caffeine on Fat Oxidation N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Completed NCT04113239 - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation NCT04373525 - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed NCT03362099 - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) Phase 4
Recruiting NCT05857670 - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting NCT04774445 - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes N/A
Recruiting NCT05759143 - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing N/A
Active, not recruiting NCT04920513 - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.